A new trading day began on Tuesday, with Prelude Therapeutics Inc (NASDAQ: PRLD) stock price down -0.73% from the previous day of trading, before settling in for the closing price of $5.48. PRLD’s price has ranged from $1.66 to $6.80 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 9.31%. With a float of $21.18 million, this company’s outstanding shares have now reached $42.06 million.
Let’s determine the extent of company efficiency that accounts for 128 employees. In terms of profitability, gross margin is 56.54%, operating margin of -4155.11%, and the pretax margin is -3792.46%.
Prelude Therapeutics Inc (PRLD) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Prelude Therapeutics Inc is 61.51%, while institutional ownership is 29.69%.
Prelude Therapeutics Inc (PRLD) Earnings and Forecasts
In its latest quarterly report, released on 6/30/2024, the company reported earnings of -0.45 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.49 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 9.31% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 30.10% during the next five years compared to -43.14% drop over the previous five years of trading.
Prelude Therapeutics Inc (NASDAQ: PRLD) Trading Performance Indicators
Here are Prelude Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 7.83.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.93, a number that is poised to hit -0.47 in the next quarter and is forecasted to reach -1.60 in one year’s time.
Technical Analysis of Prelude Therapeutics Inc (PRLD)
Looking closely at Prelude Therapeutics Inc (NASDAQ: PRLD), its last 5-days average volume was 0.29 million, which is a jump from its year-to-date volume of 88521.0. As of the previous 9 days, the stock’s Stochastic %D was 31.10%. Additionally, its Average True Range was 0.67.
During the past 100 days, Prelude Therapeutics Inc’s (PRLD) raw stochastic average was set at 60.92%, which indicates a significant increase from 40.87% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 175.00% in the past 14 days, which was higher than the 124.59% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.93, while its 200-day Moving Average is $4.15. However, in the short run, Prelude Therapeutics Inc’s stock first resistance to watch stands at $5.55. Second resistance stands at $5.66. The third major resistance level sits at $5.83. If the price goes on to break the first support level at $5.26, it is likely to go to the next support level at $5.09. Should the price break the second support level, the third support level stands at $4.98.
Prelude Therapeutics Inc (NASDAQ: PRLD) Key Stats
With a market capitalization of 299.31 million, the company has a total of 42,079K Shares Outstanding. Currently, annual sales are 0 K while annual income is -121,830 K. The company’s previous quarter sales were 0 K while its latest quarter income was -34,740 K.
